Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 10981
Country/Region: Rwanda
Year: 2018
Main Partner: United Nations High Commissioner for Refugees
Main Partner Program: NA
Organizational Type: Multi-lateral Agency
Funding Agency: enumerations.State/PRM
Total Funding: $216,717 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $12,075
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $5,610
Care: Pediatric Care and Support (PDCS) $9,927
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $21,494
Sexual Prevention: Other Sexual Prevention (HVOP) $29,192
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $68,116
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $59,873
Treatment: Pediatric Treatment (PDTX) $10,430
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_SELF 2019 1,168
HTS_SELF 15-19, Female, Directly-Assisted 2019 59
HTS_SELF 15-19, Female, Unassisted 2019 59
HTS_SELF 15-19, Male, Directly-Assisted 2019 59
HTS_SELF 15-19, Male, Unassisted 2019 59
HTS_SELF 20-24, Female, Directly-Assisted 2019 59
HTS_SELF 20-24, Female, Unassisted 2019 70
HTS_SELF 20-24, Male, Directly-Assisted 2019 83
HTS_SELF 20-24, Male, Unassisted 2019 23
HTS_SELF 25-29, Female, Directly-Assisted 2019 12
HTS_SELF 25-29, Female, Unassisted 2019 59
HTS_SELF 25-29, Male, Unassisted 2019 59
HTS_SELF 30-34, Female, Directly-Assisted 2019 12
HTS_SELF 30-34, Female, Unassisted 2019 59
HTS_SELF 30-34, Male, Directly-Assisted 2019 12
HTS_SELF 30-34, Male, Unassisted 2019 59
HTS_SELF 35-39, Female, Directly-Assisted 2019 12
HTS_SELF 35-39, Female, Unassisted 2019 59
HTS_SELF 35-39, Male, Directly-Assisted 2019 12
HTS_SELF 35-39, Male, Unassisted 2019 59
HTS_SELF 40-49, Female, Directly-Assisted 2019 59
HTS_SELF 40-49, Female, Unassisted 2019 59
HTS_SELF 40-49, Male, Directly-Assisted 2019 59
HTS_SELF 40-49, Male, Unassisted 2019 59
HTS_SELF 50+, Female, Unassisted 2019 59
HTS_SELF Directly-Assisted 2019 434
HTS_SELF FSW, Unassisted 2019 234
HTS_SELF Unassisted 2019 734
HTS_TST <5, Unknown Sex, Negative 2019 33
HTS_TST 25-29, Female, Negative 2019 7
HTS_TST 25-29, Female, Negative 2019 38
HTS_TST 25-29, Female, Negative 2019 227
HTS_TST 25-29, Female, Negative 2019 337
HTS_TST 25-29, Female, Negative 2019 1
HTS_TST 25-29, Female, Negative 2019 193
HTS_TST 25-29, Male, Negative 2019 6
HTS_TST 25-29, Male, Negative 2019 22
HTS_TST 25-29, Male, Negative 2019 155
HTS_TST 25-29, Male, Negative 2019 1
HTS_TST 25-29, Male, Negative 2019 197
HTS_TST 30-34, Female, Negative 2019 8
HTS_TST 30-34, Female, Negative 2019 38
HTS_TST 30-34, Female, Negative 2019 227
HTS_TST 30-34, Female, Negative 2019 348
HTS_TST 30-34, Female, Negative 2019 1
HTS_TST 30-34, Female, Negative 2019 197
HTS_TST 30-34, Male, Negative 2019 6
HTS_TST 30-34, Male, Negative 2019 22
HTS_TST 30-34, Male, Negative 2019 155
HTS_TST 30-34, Male, Negative 2019 1
HTS_TST 30-34, Male, Negative 2019 193
HTS_TST 35-39, Female, Negative 2019 8
HTS_TST 35-39, Female, Negative 2019 37
HTS_TST 35-39, Female, Negative 2019 227
HTS_TST 35-39, Female, Negative 2019 332
HTS_TST 35-39, Female, Negative 2019 1
HTS_TST 35-39, Female, Negative 2019 193
HTS_TST 35-39, Male, Negative 2019 6
HTS_TST 35-39, Male, Negative 2019 22
HTS_TST 35-39, Male, Negative 2019 150
HTS_TST 35-39, Male, Negative 2019 1
HTS_TST 35-39, Male, Negative 2019 202
HTS_TST 40-49, Female, Negative 2019 7
HTS_TST 40-49, Female, Negative 2019 37
HTS_TST 40-49, Female, Negative 2019 216
HTS_TST 40-49, Female, Negative 2019 322
HTS_TST 40-49, Female, Negative 2019 1
HTS_TST 40-49, Female, Negative 2019 202
HTS_TST 40-49, Male, Negative 2019 4
HTS_TST 40-49, Male, Negative 2019 22
HTS_TST 40-49, Male, Negative 2019 77
HTS_TST 40-49, Male, Negative 2019 1
HTS_TST 40-49, Male, Negative 2019 198
HTS_TST By Key Population: FSW, Negative 2019 302
HTS_TST By Key Population: People in prisons and other enclosed settings, Negative 2019 186
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 8,612
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 2
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 89
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 489
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 5
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 31
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 12
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 10
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 10
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 12
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 10
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 6
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 7
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 3
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 3
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 3
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 23
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 13
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 56
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 19
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 43
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 44
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 22
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 11
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 21
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 109
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 120
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 219
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 242
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 148
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 126
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 11
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 2
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 2
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 4
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 4
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 4
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 34
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 64
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 178
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 191
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 390
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 338
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 366
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 193
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 168
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 3
HTS_TST_POS 25-29, Female, Positive 2019 4
HTS_TST_POS 25-29, Female, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 1
HTS_TST_POS 30-34, Female, Positive 2019 3
HTS_TST_POS 30-34, Female, Positive 2019 1
HTS_TST_POS 30-34, Female, Positive 2019 1
HTS_TST_POS 30-34, Female, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 2
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 4
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 1
HTS_TST_POS By Key Population: FSW, Positive 2019 12
HTS_TST_POS By Key Population: People in prisons and other enclosed settings, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 1
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 139
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 139
PMTCT_ART Already on ART at beginning of current pregnancy 2019 40
PMTCT_ART New on ART 2019 5
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 45
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 2,093
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 25
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 10
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 35
PMTCT_EID Sum of Infant Age disaggregates 2019 35
PMTCT_STAT 25-29, Female 2019 363
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 7
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 354
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 1
PMTCT_STAT 30-34, Female 2019 363
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 7
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 354
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 1
PMTCT_STAT 35-39, Female 2019 363
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 7
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 354
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 1
PMTCT_STAT 40-49, Female 2019 363
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 7
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 354
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 1
PMTCT_STAT By Age (Numerator): 15-19 2019 94
PMTCT_STAT By Age (Numerator): 20-24 2019 531
PMTCT_STAT By Number of known positives: 20-24 2019 3
PMTCT_STAT By Number of new negative: 15-19 2019 93
PMTCT_STAT By Number of new negative: 20-24 2019 526
PMTCT_STAT By Number of new positives: 20-24 2019 1
PMTCT_STAT Number of new ANC and L&D clients 2019 2,112
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 2,093
PMTCT_STAT_den 25-29, Female 2019 362
PMTCT_STAT_den 30-34, Female 2019 357
PMTCT_STAT_den 35-39, Female 2019 357
PMTCT_STAT_den 40-49, Female 2019 357
PMTCT_STAT_den By Age (Denominator): <15-19 2019 106
PMTCT_STAT_den By Age (Denominator): 10-14 2019 2
PMTCT_STAT_den By Age (Denominator): 20-24 2019 571
PP_PREV Age/sex: 10-14 Female 2019 750
PP_PREV Age/sex: 15-19 Female 2019 2,005
PP_PREV Age/sex: 20-24 Female 2019 2,250
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 5,005
PP_PREV Sum of Age/Sex disaggregates 2019 5,005
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 1
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 1
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 2
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 7
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 8
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 17
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 17
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 6
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 9
TX_CURR 25-29, Female, Positive 2019 46
TX_CURR 25-29, Male, Positive 2019 25
TX_CURR 30-34, Female, Positive 2019 46
TX_CURR 30-34, Male, Positive 2019 25
TX_CURR 35-39, Female, Positive 2019 46
TX_CURR 35-39, Male, Positive 2019 25
TX_CURR 40-49, Female, Positive 2019 46
TX_CURR 40-49, Male, Positive 2019 25
TX_CURR Age/Sex: <1-9 2019 13
TX_CURR Age/Sex: 10-14 Female 2019 10
TX_CURR Age/Sex: 10-14 Male 2019 11
TX_CURR Age/Sex: 15-19 Female 2019 10
TX_CURR Age/Sex: 15-19 Male 2019 6
TX_CURR Age/Sex: 20-24 Female 2019 22
TX_CURR Age/Sex: 20-24 Male 2019 5
TX_CURR Age/Sex: 50+ Female 2019 62
TX_CURR Age/Sex: 50+ Male 2019 53
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 485
TX_CURR Sum of age/sex disaggregates 2019 16
TX_NEW 25-29, Female, Positive 2019 4
TX_NEW 25-29, Male, Positive 2019 3
TX_NEW 30-34, Female, Positive 2019 4
TX_NEW 30-34, Male, Positive 2019 3
TX_NEW 35-39, Female, Positive 2019 4
TX_NEW 35-39, Male, Positive 2019 3
TX_NEW 40-49, Female, Positive 2019 4
TX_NEW 40-49, Male, Positive 2019 3
TX_NEW By Age/Sex: 15-19 Female 2019 2
TX_NEW By Age/Sex: 20-24 Female 2019 5
TX_NEW By Age/Sex: 20-24 Male 2019 2
TX_NEW By Age/Sex: 50+ Female 2019 3
TX_NEW By Age/Sex: 50+ Male 2019 3
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 46
TX_NEW People in prisons and other enclosed settings 2019 1
TX_NEW Pregnancy status 2019 5
TX_NEW Sum of Age/Sex disaggregates 2019 15
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 562
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 112
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 28
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 113
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 28
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 113
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 28
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 111
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 28
TX_PVLS_den Denominator: Indication: Routine 2019 450
TX_PVLS_den Denominator: Indication: Targeted 2019 112
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 24
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 12
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 40
TX_RET Numerator by Status: Pregnant 2019 2
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 46
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 2
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 28
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 15
TX_RET_den Denominator by Status: Pregnant 2019 2
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 1,150
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 32
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 32
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 688
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 397
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 5
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 6
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 13
Cross Cutting Budget Categories and Known Amounts Total: $15,000
Gender: Gender Based Violence (GBV) $15,000
GBV Prevention
Implementation
Capacity building
Collection and Use of Gender-related Strategic Information